Ex Parte Maggiore et al - Page 6

                Appeal 2006-2897                                                                                
                Application 10/074,715                                                                          

                        See also Ans. at 4 (Steaffens provides “a cell lysing agent                             
                        (dispersing), which is ethanol”); FOA at 5 (“ethanol” is “cell lysing                   
                        or dispersing agent”).                                                                  
                     2. Steaffens discloses amounts of chelating agents (0.1% to 30% v/v)                       
                        and cell lysing agents (0.01 mM to 100 mM) that encompass or                            
                        substantially overlap Appellants’ claimed ranges.  Col. 6, ll. 31-34.                   
                        See also Ans. at 7; FOA at 5.                                                           
                     3. Steaffens’ solubilizing agents include “alcohols such as ethanol,”                      
                        one of Appellants’ preferred lysing agents.  See, e.g., col. 4,                         
                        ll. 33-38.                                                                              
                     4. Steaffens’ chelating agents include EDTA.  See, e.g., col. 6, l. 14.                    
                     5. Steaffens’ stabilizing compositions are “aqueous.”  See, e.g., col. 1,                  
                        ll. 12-13.                                                                              
                     6. While not required by claim 12, Steaffens also discloses a                              
                        preservative in an amount overlapping the claimed range.  See, e.g.,                    
                        col. 4, l. 66-col. 5, l. 6; col. 6, ll. 1-3 & 12-53.                                    
                     7. Figard discloses aqueous compositions for immunoassays, inter alia,                     
                        “useful for stabilizing the immunoreactivity of antigens.”  Col. 2,                     
                        ll. 39-54.                                                                              
                     8. Figard’s teachings are relevant to Appellants’ dependent claims and                     
                        are not necessary to support the Examiner’s § 103(a) rejection of                       
                        claim 12.                                                                               






                                                       6                                                        

Page:  Previous  1  2  3  4  5  6  7  8  9  10  11  12  13  Next

Last modified: September 9, 2013